An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori

被引:0
|
作者
van Zanten, SJOV
Flook, N
Chiba, N
Armstrong, D
Barkun, A
Bradette, M
Thomson, A
Bursey, F
Blackshaw, P
Frail, D
Sinclair, P
机构
[1] Dalhousie Univ, Queen Elizabeth II Hlth Sci Ctr, Dept Med, Halifax, NS B3H 2Y9, Canada
[2] Univ Alberta, Dept Family Med, Edmonton, AB T6G 2M7, Canada
[3] Misericordia Community Hlth Ctr, Edmonton, AB, Canada
[4] McMaster Univ, Div Gastroenterol, Hamilton, ON, Canada
[5] Surrey G1 Clin Res, Guelph, ON, Canada
[6] McMaster Univ, Dept Med, Hamilton, ON L8S 4L8, Canada
[7] Hamilton Hlth Sci Corp, Div Gastroenterol, Hamilton, ON, Canada
[8] McGill Univ, Dept Med, Montreal, PQ H3A 2T5, Canada
[9] McGill Univ, Ctr Hlth, Div Gastroenterol, Montreal, PQ H3A 2T5, Canada
[10] Univ Laval, Dept Med, Quebec City, PQ G1K 7P4, Canada
[11] CHU Quebec, Dept Gastroenterol, Quebec City, PQ, Canada
[12] Univ Alberta, Dept Med, Edmonton, AB, Canada
[13] Mem Univ Newfoundland, Hlth Sci Ctr, St John, NF, Canada
[14] Surrey Mem Hosp, Surrey, BC, Canada
[15] Dalhousie Univ, Coll Pharm, Halifax, NS B3H 3J5, Canada
[16] AstraZeneca Canada Inc, Mississauga, ON, Canada
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To provide Canadian primary care physicians with an evidence-based clinical management tool, including diagnostic and treatment recommendations, for patients who present with uninvestigated dyspepsia. Recommendations: The management tool has 5 key decision steps addressing the following: (1) evidence that symptoms originate in the upper gastrointestinal tract, (2) presence of alarm features, (3) use of nonsteroidal anti-inflammmatory drugs (NSAIDs), (4) dominant reflux symptoms and (5) evidence of Helicobacter pylori infection. All patients over 50 years of age who present with new-onset dyspepsia and patients who present with alarm features should receive prompt investigation, preferably by endoscopy. The management options for patients with uninvestigated dyspepsia who use NSAIDs regularly are: (1) to stop NSAID therapy and assess symptomatic response, (2) to treat with NSAID prophylaxis ii NSAID therapy cannot be stopped or (3) to refer for investigation. Gastroesophageal reflux disease can be diagnosed clinically if the patient's dominant symptoms are heartburn or acid regurgitation, or both; these patients should be treated with acid suppressive therapy. The remaining patients should be tested for H. pylori infection, and those with a positive result should be treated with H. pylori-eradication therapy. Those with a negative result should have their symptoms treated with optimal antisecretory therapy or a prokinetic agent. Validation and evidence: Evidence for resolution of the dyspepsia symptoms was the main outcome measure. Supporting evidence for the 5 steps in the management tool and the recommendations for treatment were graded according to the strength of the evidence and were endorsed by consensus of committee members. If no randomized controlled clinical trials were available, the recommendations were based on the best available evidence. Literature review: Evidence was obtained from MEDLINE searches for pertinent articles published from 1966 to October 1999. The searches focused on dyspepsia, diagnosis and treatment Additional articles were retrieved through a manual search of bibliographies and abstracts from international gastroenterology conferences. Sponsors: Supported by unrestricted educational grants from AstraZeneca Canada Inc., Isotechnika Inc. and Integrated Healthcare Communications Inc.
引用
收藏
页码:S3 / S23
页数:21
相关论文
共 50 条
  • [1] An Evidence-Based Approach to the Management of Functional Dyspepsia Associated With Helicobacter pylori Infection
    Lee, Shou-Wu
    Peng, Yen-Chun
    Tung, Chun-Fang
    Lee, Teng-Yu
    Chang, Chi-Sen
    Yeh, Hong-Zen
    [J]. GASTROENTEROLOGY RESEARCH, 2014, 7 (01) : 17 - 22
  • [2] Evidence-Based Approach to Dyspepsia: From Helicobacter pylori to Functional Disease
    Wee, Eric W. L.
    [J]. POSTGRADUATE MEDICINE, 2013, 125 (04) : 169 - 180
  • [3] Review article:: Helicobacter pylori and uninvestigated dyspepsia
    Fennerty, MB
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 : 52 - 57
  • [4] 'Test and Treat' approach for the management of uninvestigated dyspepsia in Hong Kong-Is it still valid in an era of decline in Helicobacter pylori infection?
    Siu, D. K. F.
    Wu, J. C. Y.
    Chan, F. K. L.
    Sung, J. J. Y.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 : A71 - A71
  • [5] Systematic review of the epidemiological evidence on Helicobacter pylori infection and nonulcer or uninvestigated dyspepsia
    Danesh, J
    Lawrence, M
    Murphy, M
    Roberts, S
    Collins, R
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (08) : 1192 - 1198
  • [6] Helicobacter pylori among patients with uninvestigated dyspepsia: issues to be remembered
    Pellicano, Rinaldo
    Durazzo, Marilena
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 30 (03) : 278 - 279
  • [7] Helicobacter pylori "test-and-treat'' strategy is not suitable for the management of patients with uninvestigated dyspepsia in Shanghai
    Li, XB
    Liu, WZ
    Ge, ZZ
    Chen, XY
    Shi, Y
    Xiao, SD
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2005, 40 (09) : 1028 - 1031
  • [8] Treatment of uninvestigated dyspepsia with cisapride for patients with negative Helicobacter pylori serologies
    Kearney, DJ
    Avins, AL
    McQuaid, KR
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2000, 95 (09): : 2212 - 2217
  • [9] Helicobacter pylori and dyspepsia management
    Shah, MV
    [J]. EAST AFRICAN MEDICAL JOURNAL, 2000, 77 (08) : 405 - 405
  • [10] Primary care dyspepsia management in the Helicobacter pylori (HP) era.
    Greenaway, JR
    Cann, PA
    [J]. GUT, 1997, 40 : F230 - F230